Indian multinational pharmaceutical company Lupin Limited (BSE:500257, NSE:LUPIN) announced on Tuesday plans to partner with US conglomerate Honeywell International Inc (NASDAQ:HON) to integrate Honeywell's Solstice Air propellant in its pressurised metered-dose inhalers for asthma and chronic obstructive pulmonary disease (COPD).

This move positions Lupin as the first Indian pharmaceutical company to adopt the hydrofluoroolefin propellant at scale. Solstice Air (HFO-1234ze cGMP) offers a sustainable, non-flammable alternative to hydrofluorocarbon-based propellants, potentially cutting greenhouse gas emissions by up to 99.9%.

The initiative reflects Lupin's strategic commitment to reducing the environmental footprint of its respiratory treatments while maintaining efficacy for patients.

The agreement remains contingent on the successful negotiation and execution of definitive documents between the two companies.